Management of depression during the perinatal period: state of the evidence

Idan Falek*, Mary Acri, Joanna Dominguez, Jennifer Havens, Mary McCord, Sarah Sisco, Wendy Wilcox and Kimberly Hoagwood

Abstract
Background: Perinatal depression (PND) is a prevalent ailment that affects both the woman and her family. Addressing PND in primary health care, such as pediatrics and obstetric care settings, has been proposed as an effective way to identify and treat women.

Objective: The purpose of this study is to examine best practices for management of PND in obstetric and pediatric settings, as well as investigate the evidence that supports the guidelines.

Methods: Guidelines were identified through a literature search and discussion with experts in the field of perinatal depression, while evidence was examined through a literature search of reviews and thereafter experimental studies.

Results: Twenty-five guidelines, across 17 organizations were retained for analysis. Findings suggest that there is little or varied guidance on the management of PND, as well as a lack of specificity. Treatment was the topic most frequently reported, followed by screening. However best practices vary greatly and often contradict one another. Across all areas, there is inadequate or contrasting evidence to support these guidelines.

Conclusions: Although there was consensus on the key steps in the pathway to care, the review revealed lack of consensus across guidelines on specific issues relating to identification and management of depression during the perinatal period. Clinicians may use these recommendations to guide their practice, but they should be aware of the limitations of the evidence supporting these guidelines and remain alert to new evidence. There is a clear need for researchers and policymakers to prioritize this area in order to develop evidence-based guidelines for managing perinatal depression.

Keywords: Perinatal depression, Guidelines for management, Pathway to care, Obstetric care, Pediatric care

Introduction
Approximately one in every ten women experiences major depression within their lifetime [4, 77], which is twice as high as rates of depression amongst men [5, 17, 39]. The perinatal period, which encompasses pregnancy and the postpartum period, is one of the most vulnerable time points for the onset of depression among women [15]. In one systematic review across varying countries, 7.4% of women met criteria for depression during the first trimester, 12.8% met criteria during the second trimester, and 12.0% during the third [13], while between 10 and 15% of women have been found to experience depression during the postpartum period [9, 35].

The entire family is impacted by perinatal depression (PND). In addition to being one of the leading causes...
of disability amongst adults and an accelerant to poor health and premature mortality [18, 31, 75], infants born to women experiencing depression have a heightened risk for low birth weight and premature delivery, and demonstrate worse cognitive performance, behavior problems, and heightened anger [14, 71]. Caregiver depression also undermines the quality of parenting, resulting in decreased parental involvement and warmth and an increased risk of child maltreatment [25, 45].

Identifying PND within health settings has been proposed as an effective way to facilitate detection and treatment [40, 51]. The American Academy of Pediatrics [8], for example, advises screening mothers in pediatric settings at 1, 2, 4, and 6 months post-delivery, which correspond to their child’s well-child visit [29]. Integrating mental health services into health settings reduces logistical barriers to access [61], provides frequent and consistent contact [40, 51], and potentially decreases perceptual barriers such as stigma [61, 69]. To this end, several recent studies have found that female caregivers preferred and were more likely to seek mental health treatment when offered in primary care and obstetric settings [32, 51].

There are significant barriers to addressing PND in health settings, however; providers cite concerns about being too busy to screen, not feeling confident addressing maternal depression, and lacking knowledge about available mental health resources to refer caregivers to [21, 28, 30, 34, 72]. To this end, Lancaster et al. [40] found less than half of obstetricians reported that residency prepared them to diagnose depression. Consequently, most women with perinatal depression are not identified, in one study, only 26% of pregnant women who met criteria for depression or anxiety were identified by their obstetricians as having a mental health problem [66]. Further, most women do not receive mental health services at all for any mental health condition [1, 24, 62], with a systematic review finding that 8.6% of women with antenatal depression and 6.3% of women with postpartum depression received adequate treatment [24]. This is further evidenced by Kessler et al. [37] national epidemiology study of major depressive disorder (MDD) finding that 51.6% of 12-month cases received health care treatment for MDD, with 21.7% of 12-month cases being adequate treated. A recent analysis of the National Survey on Drug Use and Health, for example, found pregnant women were statistically less likely to receive treatment for depression than women who were not pregnant, and their perceived unmet need was statistically greater irrespective of whether they received treatment [62]. Coalescing best practices for the management of PND in health settings can benefit providers who may not feel equipped or lack knowledge about how to identify and address of depression during a particularly vulnerable period in the health and wellbeing of families. It may also be valuable to compare guidelines from different sources to examine where they may overlap and diverge to improve management practice. Accordingly, this paper aims to review and synthesize best practice guidelines in addressing perinatal depression in health settings. We review and analyze guidelines from national and international sources, covering 1990 to 2021, compare them to current practice, and make recommendations for strengthening both the evidence base and its implementation to improve maternal and familial health.

Methods

To identify guidelines and evidence from the empirical literature, two separate steps were undertaken: (1) a search of guidelines, and (2) a review of the literature to examine the evidence. In order to conduct a comprehensive search of guidelines, three methods were employed: (1) a search of the Guideline International Network using the term depression, (2) website and Google searches, and (3) discussions with experts in the field of perinatal depression.

Inclusion and exclusion criteria

Guidelines were included if they:

1. Described the management of perinatal depression (corresponding to the period of pregnancy and/or the first 12 months after childbirth, although the postpartum period may vary across sources) in pediatrics or obstetric settings,
2. Were published between 1990 and 2021, and
3. Were written in English.

A total of 65 guidelines were retrieved; of these, 25 met the above criteria and were included in this study. See Figure 1.

Next, we reviewed the research literature to examine evidence for the management of perinatal depression as described by the guidelines. To locate this literature, we undertook an online search using Google Scholar and PubMed databases with search limits restricted by year (1990–2021) and language (English). Search terms used for the literature review included two categories: perinatal period (pregnancy, postpartum) and depression management (screening, assessment to confirm the diagnosis, suicide assessment, treatment, reassessment, remission, treatment of refractory depression and care management). Search terms within the perinatal period category were linked with “or”, and the perinatal period and one of the depression management categories were linked with “and” to capture studies that included at least...
one search term from both the first and second categories. If meta-analyses and systematic reviews were identified, the search was ended. If none were found, the search was expanded to include individual experimental, quasi-experimental, and non-experimental studies.

**Results**

The 25 guidelines were published across 17 organizations, with six organizations publishing multiple guidelines. More than half of the guidelines (n = 14, 56%) were issued by international bodies; the remaining 11 (44%) were issued by the United States. The international guidelines included in the reviews spanned multiple regions as defined by the World Bank [74], including Europe and Central Asia (n = 6, 43%; United Kingdom, Netherlands, Spain, and Nordic region [Denmark, Finland, Iceland, Norway, Sweden]), East Asia and Pacific (n = 5, 36%; Australia, New Zealand, and Singapore), and North America (n = 3, 21%; Canada). National guidelines were published by a variety of organizations including American Academy of Pediatrics (AAP), American College of Obstetricians and Gynecologists (ACOG), United States Preventive Services Task Force (USPSTF), Postpartum Support International (PSI), National Committee for Quality Assurance (NCQA), and Kaiser Permanente. Guidelines were published between 2009 and 2020, with more than a quarter (n = 7, 28%) being published in 2018. See Table 1.

Following previous guideline reviews of depression [44], results were explored by the following categories: screening, assessment to confirm the diagnosis, suicide assessment, treatment, reassessment, remission, treatment of refractory depression and care management. See Table 2.

**Screening**

**Guideline Recommendations**

The majority of guidelines (n = 18, 72%) issued recommendations on screening for PND, and of them 16 (89%) provided multiple recommendations.

**Screening timeframe**

Fourteen guidelines (78%) recommended routine screening during the perinatal period. Of them, eight (57%) recommended screening during both the prenatal and postpartum period. Half (n = 4, 50%) of the guidelines provided specific screening intervals that permitted the integration of screening with existing routine care, allowing the mother who initially may not be comfortable to disclose to do so at a later date, maximizing the opportunity to engage if they miss a visit, and reducing false-positive and false-negative results [27, 29, 57]. Two
guidelines (11%) stated that because the evidence was inconsistent, an optimal screening interval was unknown and that no recommendations regarding specific frequency and timing could be made.

**Setting**

More than half of the guidelines (n = 12, 67%) recommended screening locations; of them, seven (58%) recommended screening in obstetric settings, three (25%) recommended screening in pediatric settings, and two (17%) recommended screening in both obstetric and pediatric settings. These settings were identified as optimal because screenings could be readily integrated with existing care, and permitted fostering a longitudinal relationship between providers and women, which facilitated building trust and may in turn lead to disclosure of depressive symptoms [11, 27, 29, 55].

**Instrumentation**

Twelve guidelines (67%) also recommended specific screening instruments, with six guidelines (50%) recommending multiple instruments including the Edinburgh
Postnatal Depression Scale (EPDS; \(n=8, 67\%\)), and the two and nine-question versions of the Patient Health Questionnaire (PHQ-9; \(n=3, 12\%\); PHQ-2; \(n=3, 12\%\)). One guideline (6%) cited that there were no accurate screening tools for identifying who is at risk of perinatal depression, as more data were needed before incorporating perinatal risk factors into the screening tools. Variability was also found in clinical cutoffs for each instrument, although not all guidelines provided cutoff scores. See Table 3.

### Summary of literature review

A recent review for the United States Preventive Services Task Force (USPSTF), which synthesized 33 studies, found that screening women during the perinatal period reduced the prevalence of depression [54]. Notably, the review cited limitations of a relatively small number of studies, few trials with good applicability to primary care, and many studies with very small sample sizes. These limitations were further recognized in Milgrom and Gemmill’s [47] review of an undisclosed number of studies, in which they found that high-quality evidence about the clinical effectiveness of screening programs was slow to emerge, with relevant studies being rare and having small samples. No trials tested the effectiveness of screening in reducing perinatal morbidity were of high enough quality to meaningfully inform clinical practice [47]. Additionally, there was an insufficient quality and quantity of available evidence to establish the optimal time intervals to screen [47]. The lack of sufficient evidence was reinforced in Ukatu et al.’s [70] review of 68 articles on postpartum depression (PPD) screening tools. Findings suggested that no instrument could be deemed best at accurately detecting PPD on the basis of sensitivity and specificity, and there was no evidence for a recommended time duration in which screening should be completed.
Assessment to confirm diagnosis

Guideline recommendations

Slightly over one-third of the guidelines \((n = 9, 36\%\) recommended conducting an assessment to confirm depression after screening. Three guidelines \((33\%\) made multiple recommendations. The remaining guidelines \((n = 16, 64\%\) did not reference confirmation of a diagnosis post-screening.
Assessment by severity
Six of the nine guidelines (67%) made recommendations to confirm a diagnosis based on severity. In less severe situations, which were defined as depression without suicidal ideation or risk of harm, a score of 10–12 on the EPDS or a score of 10–15 on the PHQ-9, four guidelines (67%) recommended discussing the specific mental health concerns and symptoms identified in the screening tool to confirm the diagnosis. For more severe scores, defined as provider concern for suicidal ideation, risk of harm, or severe mental illness, three guidelines (50%) recommended an integrated frontline or emergency mental health provider deliver immediate triage to confirm diagnosis. Only one of the nine guidelines provided recommendations for both low- and high-risk screening results.

Assessment by instrumentation
Two guidelines (22%) recommended a full psychosocial assessment or referral to the woman's general practitioner if she met criteria based upon the PHQ-2; this was irrespective of severity. Nearly half of the guidelines (n = 4, 44%) specified that the EPDS should be repeated within 2–4 weeks if the respondent scored a 10 or higher to confirm diagnosis, and a high EPDS score warranted further assessment and a referral to a primary care provider or mental health professional to diagnose. The remaining three guidelines (33%) did not offer a recommendation as to which method of assessment to use.

Summary of literature review
Although it is widely recognized that a positive screening result does not qualify as a diagnosis, little evidence was found supporting an assessment to confirm diagnosis, leading to nearly 50–70% of women remaining undiagnosed [24]. Milgrom and Gemmill [47] defined best practice as systematically following every positive screen with an offer of a diagnostic assessment. However, they cautioned that no evidence is available to support or refute this practice [47]. In addition, research is limited concerning standardized methods to diagnose PND, although several sources note that it would be feasible to incorporate assessments to confirm diagnosis into perinatal care [48, 49].

Suicide assessment
Guideline recommendations
Thirteen guidelines (52%) addressed suicide assessment; of them, six (46%) recommended an immediate evaluation, such as a comprehensive suicide risk assessment (SRA), in an emergency setting or by a crisis team. More than half of the guidelines (n = 7, 54%) recommended referring the respondent to a mental health specialist or psychiatrist and closely monitoring the woman's well-being in the case suicidal risk was present. The remaining 12 guidelines (48%) did not address suicide assessment or make a recommendation for the management of suicide.

Summary of literature review
The literature cited the importance of an emergency management protocol for ensuring women with a positive screening result for suicidal ideation are engaged in care; protocols may include: (1) medical providers verifying suicidality, (2) triggering emergency psychiatric consultation, treatment, transport (by ambulance), or admission, (3) facilitating open communication between the perinatal care team and the psychiatric team and defining the respective roles of all members, and (4) identifying medication, resources, support staff and family, and other tools needed by personnel at each stage [36, 64]. However, no evidence was found concerning the overall management of suicidality, including implementation, and its impact upon reducing suicide risk.

Treatment
Guideline recommendations
Almost all of the guidelines (n = 21, 84%) included treatment recommendations, with most (n = 20, 95%) providing multiple recommendations. Further, 14 guidelines (67%) offered recommendations by severity. See in Table 4.

Indeterminate to mild severity
Indeterminate to mild severity was defined by a PHQ-9 score of 5–9, an EPDS score of less than 10, or undefined. Three guidelines (21%) recommended supportive care, including psychoeducation and emotional support provided in primary or obstetric care or a community health setting. Antidepressants or psychotherapy were not recommended for this severity level.

Mild to moderate severity
Mild to moderate depression was either undefined or defined by a PHQ-9 score of 10–14 or EPDS score of 10–12. Twelve guidelines (86%) recommended treating mild to moderate symptoms with psychotherapy, such as cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT), psychodynamic therapy (PDT), non-directive counseling in home visits, family therapy, and other counseling, in group or individual format. Treatment was recommended to be conducted through referral to a secondary mental health professional (n = 5, 42%), either a referral or the clinician (n = 3, 25%), or the
| Guideline | Treatment (intervention; provider) | Severity levels | Across severity levels | Alternative treatment |
|-----------|-----------------------------------|----------------|-----------------------|-----------------------|
|           | Indeterminate to Mild             | Mild to Moderate | Moderate to Severe    | Severe                | Suicidal risk |           |
| 1. Alhusen and Alvarez [6] | N/A                               | N/A             | N/A                   | N/A                   | N/A          | •Psychoeducation (N/A; unspecified) •Psychotherapy (CBT, IPT, group therapy; unspecified) •Pharmacology (SSRIs; unspecified) |
| 2. Austin et al. [11] | EPDS (> 10) •Psychoeducation (N/A; PCP or referral) | EPDS (10–12) •Psychotherapy (CBT, IPT, PDT, non-directive counseling; PCP or referral) | N/A                   | N/A                   | N/A          | N/A          |
| 3. Austin et al. [10] | N/A                               | Undefined •Psychoeducation (N/A; PCP and referral) •Psychotherapy (directive counseling; PCP and referral) | Undefined •Combined psychotherapy (unspecified) and pharmacology (SSRIs; PCP and referral) | EPDS (> 13) •ECT (N/A; referral) | N/A          | N/A          |
| 4. Brock [16] | N/A                               | N/A             | N/A                   | N/A                   | N/A          | •Psychotherapy (unspecified; unspecified) •Pharmacology (unspecified; unspecified) |
| 5. Chua et al. [22] | N/A                               | N/A             | N/A                   | N/A                   | N/A          | •Psychoeducation (N/A; unspecified) •Psychotherapy (unspecified; unspecified) |
| 6. Committee on Obstetric Practice [23] | N/A                               | N/A             | N/A                   | N/A                   | N/A          | •Psychotherapy (CBT, IPT; unspecified) |
| 7. Curry et al. [26] | N/A                               | N/A             | N/A                   | N/A                   | N/A          | N/A          |
### Table 4 (continued)

| Guideline | Treatment (intervention; provider) | Across severity levels | Alternative treatment |
|-----------|----------------------------------|-----------------------|----------------------|
| **Guideline** | **Severity levels** | **Indeterminate to Mild** | **Mild to Moderate** | **Moderate to Severe** | **Severe** | **Suicidal risk** | **Across severity levels** | **Alternative treatment** |
| 8. Earls et al. [29] | • Undefined • Psychoeducation (N/A; PCP) | N/A | N/A | N/A | N/A | • Psychoeducation (N/A; referral) • Psychotherapy (unspecified; referral) • Pharmacology (unspecified; referral) | N/A | N/A |
| 9. MacQueen et al. [46] | N/A | • Undefined • Psychotherapy (CBT, IPT; unspecified) | • Undefined • Pharmacology (unspecified; unspecified) • ECT (N/A; unspecified) | N/A | N/A | N/A | N/A | N/A |
| 10. Molenaar et al. [50] | N/A | • Undefined • Psychotherapy (CBT, IPT; unspecified) | N/A | • Undefined • Pharmacology (unspecified; unspecified) • ECT (N/A; referral) | N/A | N/A | N/A | N/A |
| 11. NICE [52] | N/A | • Undefined • Psychotherapy (CBT, IPT; referral) | • Undefined • Combined psychotherapy (CBT, IPT) and pharmacology (SSRIs, TCAs, SNRIs; referral) | • Undefined • ECT (N/A; referral) | N/A | N/A | N/A | N/A |
| 12. Nordeng and Jettestad [53] | N/A | • Undefined • Psychotherapy (CBT, family therapy; unspecified) | N/A | N/A | N/A | • Psychotherapy (CBT, family therapy; unspecified) | N/A | N/A |
| 13. O’Hara and Engelinger [55] | N/A | • Undefined • Psychotherapy (CBT, IPT, BA; referral) | N/A | N/A | N/A | • Psychotherapy (CBT, IPT, BA; referral) • Pharmacology (SSRIs, TCAs, SNRIs, NaSSAs; unspecified) • Electronic mental health support (apps; self-administered) | N/A | N/A |
| 14. Rafferty et al. [57] | N/A | • Undefined • Psychoeducation (N/A; referral) • Psychotherapy (CBT; referral) | • Undefined • Pharmacology (SSRIs; referral) | N/A | N/A | • Psychoeducation (N/A; referral) | N/A | N/A |
| Guideline | Treatment (intervention; provider) | Severity levels | Across severity levels | Alternative treatment |
|-----------|-----------------------------------|-----------------|-----------------------|-----------------------|
|           | Indeterminate to Mild             | Mild to Moderate | Moderate to Severe    | Severe                | Suicidal risk        |
| 15. RNAO [58] | N/A                                 | Undefined        | Undefined             | N/A                   | N/A                  | N/A                  |
|           |                                    | Psychotherapy (CBT, IPT, referral) | Pharmacology (unspecified; PCP) | Combined psychotherapy (CBT, IPT) and pharmacology (unspecified; PCP or referral) | N/A                  | BLT (N/A; self-administered) |
| 16. Robson et al. [59] | N/A                                 | N/A              | N/A                  | N/A                   | N/A                  | N/A                  |
|           |                                    | Undefined        | Pharmacology (SSRIs, TCAs; PCP and referral) | N/A                  | N/A                  | N/A                  |
| 17. SIGN [63] | N/A                                 | Undefined        | Pharmacology (SSRIs, TCAs; PCP and referral) | N/A                  | N/A                  | N/A                  |
| 18. Siu et al. [65] | N/A                                 | N/A              | N/A                  | N/A                   | N/A                  | N/A                  |
|           |                                    | Psychotherapy (CBT, IPT, PDT, PCP or referral) | Pharmacology (SSRIs, TCAs; PCP and referral) | N/A                  | N/A                  | Psychotherapy (CBT; unspecified) Pharmaco logy (unspecified; unspecified) |
| 19. Sparks et al. [68] | PHQ-9 (5–9)                        | PHQ-9 (10–14)    | PHQ-9 (15–19)         | PHQ-9 (20–27)         | N/A                  | N/A                  |
|           | Psychoeducation (N/A; PCP or referral) | Combined psychotherapy (CBT) and pharmacology (unspecified; PCP and referral) | N/A                  | ECT (N/A; unspecified) | N/A                  | BLT (N/A; self-administered) |
| 20. Williams et al. [73] | N/A                                 | Undefined        | Pharmacology (unspecified; PCP and referral) | ECT (N/A; referral)   | N/A                  | N/A                  |
| 21. Yonkers et al [76] | N/A                                 | N/A              | N/A                  | N/A                   | N/A                  | N/A                  |

BA behavioral action; BLT bright light therapy; CBT cognitive behavioral therapy; ECT electroconvulsive therapy; IPT interpersonal psychotherapy; NaSSAs noradrenergic and specific serotonergic antidepressants; PCP primary care provider; PDT psychodynamic therapy; SSRI selective serotonin reuptake inhibitor; SNRI serotonin and norepinephrine reuptake inhibitors; TCAs tricyclic antidepressants
clinician and an integrated mental health specialist (n = 1, 8%). Three guidelines (25%) did not specify a treatment setting. Additionally, four of the twelve guidelines (33%) recommended pairing psychotherapy with psychoeducation. Although most guidelines cited that medication is not necessary, one guideline (8%) suggested shared-decision making around using pharmacology treatment.

**Moderate to severe**
Nine guidelines (64%) provided recommendations for moderate to severe depression, which was either undefined or defined by PHQ-9 score of 15–19. Six guidelines (67%) recommended pharmacology as the first-line of treatment, and of them, selective serotonin reuptake inhibitors (SSRIs) were the most commonly cited (n = 2, 33%), followed by tricyclic antidepressants (TCAs; n = 1, 17%). Medication should be highly considered if she has expressed preference for them, has had previous positive response to medications, or has declined psychotherapy [22], National Institute for Health and Care Excellence [52]; Scottish Intercollegiate Guidelines [63]. Guidelines recommended a referral for pharmacological treatment, with two guidelines (33%) recommending the mental health specialist be in contact with the clinician around treatment. Noteworthy, one guideline (17%) recommended the primary clinician prescribe medication. Electroconvulsive therapy (ECT) was recommended by two of the six guidelines (22%) during pregnancy and/or postpartum period if the woman was unable to tolerate or take medications. ECT may be delivered by referral (n = 1, 50%) or did not specify who may deliver the treatment (n = 1, 50%).

Three guidelines (33%) recommended a combination of psychotherapy, such as cognitive behavioral therapy (CBT) or interpersonal psychotherapy (IPT), and pharmacology, such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and serotonin and norepinephrine reuptake inhibitors (SNRIs). Although medication alone was recommended as an alternative if psychotherapy was unavailable, psychotherapy alone was not recommended. This combined therapeutic and antidepressant treatment course is recommended to be delivered through a referral while collaborating with the clinician (n = 2, 67%) or referral alone (n = 1, 33%).

**Severe**
Severe depression was either undefined or defined as a PHQ-9 score of 20–27, EPDS score of 12–13, or EPDS score of greater than 13. Of the nine guidelines (64%) that provided recommendations for severe symptoms, four (44%) recommended a referral to electroconvulsive therapy (ECT) and four (44%) recommended a combined psychotherapy (e.g., CBT, IPT, PDT) and pharmacology (e.g., SSRIs) treatment through a referral or collaboration between provider and mental health specialist, followed by pharmacology alone (n = 1, 11%).

**Severe with suicidal risk**
Two guidelines (14%) recommended electroconvulsive therapy (ECT) during pregnancy and/or postpartum period if there was a high risk of suicide. Guidelines recommended ECT be provided by perinatal psychiatrist or in a hospital setting.

**Across severity levels**
Ten guidelines (48%) made recommendations irrespective of severity, with the majority (n = 7, 70%) making multiple recommendations. Nine of the ten (90%) recommended a referral to psychotherapy or psychosocial interventions such as cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT), psychodynamic therapy (PDT), and behavioral activation (BA), followed by six (60%) that recommended pharmacological treatment, such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and noradrenergic and specific serotonergic antidepressants (NaSSAs), and four (40%) that recommended psychoeducation throughout the perinatal period to provide support, demystify PND, and create shared decision making around treatment options.

**Alternative treatments**
In addition to evidence-based treatments such as pharmacology and psychotherapy or psychosocial interventions, four guidelines (19%) recommended alternative treatments, such as Bright Light Therapy (BLT) or electronic mental health support, such as self-guided applications and moderated online forums.

**Summary of literature review**
The literature on treatment types for PND was inconsistent. A systemic review of 32 studies on various psychotherapies, antidepressants, and collaborative-care treatments for pregnant and postpartum women found cognitive behavioral therapy (CBT) and related behaviorally based approaches improved depressive symptoms in postpartum women [54]. On the other hand, a meta-analysis of 27 studies on the efficacy of pharmacologic and psychological interventions for treatment found that treatments with interpersonal therapy components to have greater effect sizes than treatments with cognitive-behavioral components, and individually administered therapeutic interventions were more effective than a group format [67]. Letourneau et al.'s [43] systematic...
review of 36 trials of psychotherapy treatments found that although promising findings exist for IPT, CBT, and other interventions, they were unable to draw definitive conclusions regarding any one treatment that shows the most potential to influence maternal and infant outcomes. O’Connor et al. [54] also found the use of second-generation antidepressants during pregnancy may be associated with increased risk of serious maternal and infant harms to both of their physical health, while MacQueen et al. [46] found data for effectiveness of SSRI during the postpartum period. Sockol et al. [67] reported no findings on pharmacological treatments, since compared with psychological interventions there is little assessment of the efficacy of antidepressant medication. Similar to the literature on screenings, the number of included studies was relatively small, particularly for analysis of controlled effect sizes, and the quality of studies was limited [43, 46, 54, 67].

Reassessment

Guideline recommendations
Slightly more than a tenth of the guidelines (n = 3, 12%) provided recommendations pertaining to reassessment. Two guidelines (50%) recommended repeat screenings during pregnancy and the first postnatal year, during routine maternal and infant check-ups if clinically indicated. One guideline (25%) recommended reassessment via screening by a mental health provider.

Summary of literature review
Limited literature was available on reassessment. One study on PND screening found a correlation between early and late EPDS scores for ‘low-risk’ women (EPDS <10), concluding that these women may not need to be rescreened, and the limited available resources should be redirected from screening ‘low-risk’ women multiple times, towards provision of follow-up for the smaller number of women at highest risk [38]. No literature was found for other methods of reassessment.

Remission

Guideline recommendations
Two guidelines (8%) referenced remission, with one defining remission as the goal for treatment, which can be achieved through a PHQ-9 score less than 5. The other guideline explained that remission can be achieved through combining screenings and treatment with adequate support systems.

Summary of literature review
A review of 32 studies found that remission was defined in various ways, including based on diagnostic criteria using the Diagnostic and Statistical Manual of Mental Disorders (DSM–5) and cutoffs advised by instruments, such as PHQ-9 score of less than 5 or EPDS score of less 10 [24]. No other literature was available on remission, including evidence that screening or reassessing for remission was the outcome for PND.

Treatment of refractory depression

Guideline recommendations
Twelve guidelines (48%) provided recommendations in the case that PND was not responsive to treatment, with two guidelines (17%) citing multiple recommendations. Electroconvulsive therapy was recommended by half of the guidelines (n = 6, 50%) if PND was not responsive to one or more trials of antidepressants of adequate dose and duration, followed by four guidelines (33%) which recommended pharmacologic treatment if symptoms were not responsive to psychotherapy. Two guidelines (17%) recommended combining psychotherapy and pharmacologic treatment as a second-line of treatment for those with treatment resistant depression. Finally, two guidelines (17%) gave a general recommendation to review the care plan in collaboration with the woman and support network until therapeutic goals were met.

Summary of literature review
No literature was identified on treatment adjustment for PND that was not responsive to pharmacology or psychotherapy.

Care management

Guideline recommendations
Care management of PPD was discussed by more than half of the guidelines (n = 13, 52%), with one guideline (8%) making multiple recommendations. The majority (n = 11, 85%) recommended PPD be managed through a collaboration between the pediatrics or obstetric care team and mental health specialists to connect families to supportive community resources, and to refer parents for additional treatment when indicated. Only three guidelines (27%) briefly described methods to do so, such as close networks or linkages with the primary or obstetric care and mental health providers, joint case management, or Patient Centered Medical Home (PCMH). Three guidelines (23%) mentioned integrating mental or behavioral health teams into collaborative care model (CCM), however no further details were provided.
Summary of literature review
Limited research was found for care management. Grote et al. [33] collaborative care intervention in obstetric care, MOMCare, demonstrated a trend toward reducing depression severity compared to the usual care. The intervention MOMCare also resulted in higher rates of antidepressant use and reported greater levels of satisfaction with depression care received compared with the usual care group [33]. No other evidence was found on care management, whether integrative or collaborative, specific to the perinatal period.

Discussion
The purpose of this review was to examine best practices for the management of perinatal depression during pregnancy and the postpartum period as advised by 25 guidelines, and the evidence supporting guideline recommendations. Several findings warrant discussion.

Primarily, all of the guidelines were published within the last 12 years, although the inclusion criteria spanned the past 30 years. The recency of the publications suggests that there is increasing interest by professional associations, states, countries, and providers to identify, address, and manage PND. This is further evidenced by the sheer number of guidelines and organizations producing recommendations, as compared to previous guideline reviews such as Lewandowski et al. [44] review of adolescent depression that contained only eight guidelines. Notably, the mode publication year is 2018, raising a question of what occurred at that time to produce such a large number of publications. As anticipated, the guidelines all originated from high-income countries, as low- and middle-income countries may not have the capacity to manage perinatal depression in traditional healthcare settings due to the severe workforce shortage of professional providers often leading healthcare models to rely on lay health workers [12].

Overall, there is either little guidance available or recommendations varied on the management of PND from screening to treatment remission offered by the guidelines. Treatment was the most highly reported step in the pathway for managing PND, followed by screening. However, there were significant gaps that remained unaddressed particularly with respect to confirmation of depression diagnosis, management of suicidal risk, reassessment, and guidance for remission. Findings suggest that best practices vary greatly and often contradict one another. There are also significant issues around lack of specificity, including in areas that have the most guidance such as treatment and screening. For example, the recommended instrument, time interval, and settings for screening are inconsistent across guidelines. Although publishers focus their guidance based on their target audience and as such are unlikely to provide recommendations for screenings in settings outside of their field of practice, inconsistencies in screening settings were still found in guidelines that span the entire perinatal period from pregnancy to postpartum. Guidance around treatment often fails to specify how severity levels were defined or why they often overlapped in the score range. Our review found other inconsistency and ambiguity: some guidelines provided recommendations based on severity level or range, while others were issued irrespective of severity. This inconsistency across guidelines in the basic steps in the pathway to care suggest strongly the need for further research to solidify the evidence about the steps in the pathway, or at minimum build consensus around guidelines. Variability around who administers treatment was also found. Guidelines about recommendations on reassessment contradicted one another about the method, timing, and provider required to administer the assessment; confirmation of diagnosis similarly contained wide variability on method. The lack of guidance on confirming a diagnosis raises concern of how the provider proceeds with care without a diagnosis. Treatment for refractory depression varies based on impact and type of first-line of treatment. The lack of guidance on remission raises concerns of how management of PND is achievable without a clear path to ameliorate symptoms [19].

Across all areas, there is inadequate or contrasting evidence to support these guidelines, with a limited number of studies, most of which have small sample sizes or do not have high enough quality to meaningfully inform clinical practice. With little guidance for providers, it is unsurprising that many feel that management of PND is beyond their scope of practice, as they are unprepared with the proper skills and resources needed [19].

Throughout the guidelines, the role of the physician was often to screen, provide psychoeducation, and refer for services. However, it is unlikely that women would access services with referrals being offsite, as referrals alone have not been shown to translate to treatment engagement [60]. Although the guidelines acknowledge the need to collaborate with mental health professionals or integrate mental health services into their practice, there was minimal indication on how to do so. This is further evidenced by providers describing working in isolation from mental health professionals, despite being aware of the need to better integrate perinatal and mental health care to create a more holistic approach to care [19]. The lack of communication between these provider groups, often due to lack of access to medical records, is noted through limited feedback perinatal health care professionals receive from mental health providers about the mental health assessment and treatment plan [19].
Limitations
This study has several limitations to be noted. There was not a systematic review of the literature on evidence for the management of perinatal depression, warranting a more comprehensive systematic search. Additionally, for the review of the evidence, only systematic reviews, and in a few cases experimental studies, were examined. The grey literature was not reviewed, indicating that there may be additional methods to manage depression that may not have been considered.

Implications for practice
There are a wide-range of barriers for providers to address PND, including limited time and capacity, lack of available mental health specialists, dearth of materials and resources available, and inadequate mental health training [19]. These factors lead to lowered motivation and confidence to attend to women’s mental health issues [19]. Despite the acknowledged challenges, providers are motivated to learn needed skills, as they recognize the importance of addressing PND, through targeted trainings [19].

A systematic review of 1790 articles identified seven studies on strategies for professional development of health-care providers in perinatal depression [42]. Legere et al. [42] found that although the professional development interventions were diverse, the majority focused on promoting identification of perinatal depression and demonstrated modest effectiveness in improving various outcomes.

Addressing this gap requires innovative strategies to facilitate engagement, such as co-location of services. The Massachusetts Child Psychiatry Access Project (MCPAP) initiative, MCPAP for Moms, provides real-time telephone-based psychiatric consultations and care coordination for frontline providers and linkages to community-based resources [20]. Alternatively, the use of peer-led interventions may be explored, such as Screening, Education, and Empowerment (SEE) program, which is a detection and active outreach intervention for primarily poverty-impacted female caregivers who are at risk for depression led by a non-mental health paraprofessionals [2, 3]. While optimally building out the capacity for services to be offered in-house through models such as CCM, there is minimum need for consistent guidelines to inform clinical practice.

Conclusion
In sum, our review revealed lack of consensus across guidelines on specific issues relating to management of depression during the perinatal period. This is unfortunate given the high impact of lack of care during this period for both mothers and infants. Nevertheless, there was consensus on the key steps in the pathway to care, an important finding suggesting that the critical domains of care are recognized and agreed-upon. The inconsistencies with respect to instrumentation and recommendations suggest that clinicians may use these recommendations to guide their practice, but they should remain alert to new evidence that may modify the guidelines, and they should be aware of the limitation of the evidence. Findings identify the need for substantial attention by funders of research to prioritize this area in order to develop evidence-based guidelines for managing perinatal depression.

Abbreviations
AAP: American Academy of Pediatrics; ACOG: American College of Obstetricians and Gynecologists; BA: Behavioral activation; BLT: Bright light therapy; CBT: Cognitive behavioral therapy; CCM: Collaborative care model; DSM: Diagnostic and statistical manual of mental disorders; ECT: Electroconvulsive therapy; EPDS: Edinburgh Postnatal Depression Scale; GIN: Guideline International Network; IPT: Interpersonal psychotherapy; MCPAP: Massachusetts child psychiatry access project; MDD: Major depressive disorder; NaSSA: Noradrenergic and specific serotonergic antidepressants; NCQA: National Committee for Quality Assurance; PCMH: Patient Centered Medical Home; PDT: Psychodynamic therapy; PHQ: Patient Health Questionnaire; PND: Perinatal depression; PPD: Postpartum depression; PSI: Postpartum support international; SEE: Screening, education, and empowerment program; SNRI: Serotonin and nor-adrenaline reuptake inhibitors; SRA: Suicide risk assessment; SSRI: Selective serotonin reuptake inhibitors; TCA: Tricyclic antidepressants; USPSTF: United States Preventive Services Task Force.

Acknowledgements
Not applicable.

Author contributions
IF takes responsibility for the integrity of the work as a whole from inception to published article. Additional details about author’s contributions are indicated below. Conception or design of the work—IF and MA. Data collection, Data analysis and interpretation—IF and JD. Critical revision of the article—IF, MA, JH, MM, SS and WW. All authors read and approved the final manuscript.

Funding
The authors declare no funding for the research reported.

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Declarations
Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Child & Adolescent Psychiatry, NYU School of Medicine, One Park Avenue, 7th Floor, New York, NY 10016, USA. 2 New York City Health and Hospitals Corporation, 55 Water St, New York, NY 10041, USA.
Obstet Gynecol. 2010;2012(1):5–14. https://doi.org/10.1016/j.ajo.2009.09.007.

41. LeFeuvre ML, Siu AL, Bibbins-Domingo K, Baumann LC, Curry SJ, Davidson KW, Ebell M, Garcia FAP, Gillman M, Herzer JS, Grossman DJ, Kemper AR, Kurth AE, Owens DK, Phillips WR, Phipps MG, Pignone MP. Screening for suicide risk in adolescents, adults, and older adults in primary care. Ann Intern Med. 2014. https://doi.org/10.7326/M14-0483.

42. Legere LE, Wallace K, Bowen A, McQueen K, Montgomery P, Evans M. Approaches to health-care provider education and professional development in perinatal depression: a systematic review. BMC Pregnancy Childbirth. 2017. https://doi.org/10.1186/s12884-017-1431-4.

43. Letourneau NL, Dennis CL, Cosic N, Linder J. The effect of perinatal depression treatment for mothers on parenting and child development: a systematic review. Depress Anxiety. 2017;34(10):928–66. https://doi.org/10.1002/dan.22687.

44. Lewandowski RE, Acri MC, Hoagwood KE, Olfson M, Clarke G, Gardner W, Legere LE, Wallace K, Bowen A, McQueen K, Montgomery P, Evans M. Perinatal depression: implications for child mental and parenting behavior: a meta-analytic review. Clin Psychol Rev. 2000;20(5):561–91. https://doi.org/10.1016/S0191-7719(00)00010-7.

45. MacQueen GM, Frey BN, Ismail Z, Jaworska N, Steiner M, Lieshout RJV, Kennedy SH, Lam RW, Milew RV, Parikh SV, Ravindran AV, CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. Can J Psychiatry. 2016;61(9):588–603. https://doi.org/10.1177/0706706716659276.

46. Milgrom J, Gemmill AW. Screening for perinatal depression. J Best Pract Res Clin Obstet Gynaecol. 2014;28(1):13–23. https://doi.org/10.1016/j.bpobgyn.2013.08.014.

47. Miller LJ, McGlynn A, Suberlak K, Rubin LH, Miller M, Pirec V. Now what? Effects of on-site assessment on treatment entry after perinatal depression screening. J Women's Health. 2012;21(10):1046–52. https://doi.org/10.1089/jwh.2012.3641.

48. Miller L, Shade M, Vasiedy V. Beyond screening: assessment of perinatal depression in a perinatal care setting. Arch Womens Mental Health. 2009;12(5):329–34. https://doi.org/10.1007/s11126-009-0082-5.

49. Molenaar NM, Kamperman AM, Boyce P, Bergink V. Guidelines on treatment of perinatal depression with antidepressants: an international review. Aust NZ J Psychiatry. 2018;52(4):320–7. https://doi.org/10.1177/0004867418762057.

50. Mozurk W, Borovska S. Perinatal depression: implications for child mental health. Mental Health Family Medicine. 2010;7(4):239–47.

51. National Institute for Health and Care Excellence. Antenatal and postnatal mental health: clinical management and service guidance. London: National Institute for Health and Care Excellence (NICE); 2020.

52. Nordeng H, Jetté J. Depression during pregnancy and lactation. Denmark: Nordic Federation of Obstetrics and Gynaecology (NFÖG); 2015.

53. O'Connor E, Rossom RC, Henningr M, Groom HC, Borda BU. Primary care screening in pregnant and postpartum women: Evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;315(4):388–406. https://doi.org/10.1001/jama.2015.18998.

54. O'Hara MW, Engeldinger. J Treatment of postpartum depression: recommendations for the clinician. Clin Obstet Gynecol. 2018;61(3):604–14. https://doi.org/10.1097/GCO.0000000000000353.

55. Postpartum Support International. Screening recommendations. Toronto: Postpartum Support International-PSI; 2020.

56. Rafferty J, Muttert G, Earls MF, Yogman MW, Committee on Psychosocial Aspects of Child and Family Health. Incorporating recognition and management of perinatal depression into pediatric care. Am Acad Pediatr. 2019. https://doi.org/10.1542/peds.2018-3260.

57. Registered Nurses’ Association of Ontario. Assessment and interventions for perinatal depression. Toronto: Registered Nurses’ Association of Ontario; 2018.

58. Robson S, Harvey J, Yazdani A, Pettigrew I, Page L, Leung Y, et al. Perinatal anxiety and depression. Melbourne: RANZCOG; 2015.

59. Rowan P, Greisinger A, Brehm B, Smith F, McReynolds E. Outcomes from implementing systematic antepartum depression screening in obstetrics. Arch Womens Mental Health. 2012;15(2):115–20. https://doi.org/10.1007/s10737-012-0262-6.

60. Saedi S, Wall R. The case for mental health support at a primary care level. J Integr Care. 2018;26(2):130–9. https://doi.org/10.1108/JICA-10-2017-0036.

61. Sanmartin MX, Ali MM, Chen J, Dwyer DS. Mental health treatment and unmet mental health care need among pregnant women with major depressive episode in the United States. Psychiatr Serv. 2019;70(6):503–6. https://doi.org/10.1176/appps.201800433.

62. Scottish Intercollegiate Guidelines Network. Management of perinatal mood disorders: a national clinical guideline. Scotland: Scottish Intercollegiate Guidelines Network; 2012.

63. Serati M, Carnevali G. Perinatal depression. Clin Cases Psychiatry. 2018. https://doi.org/10.1007/978-3-319-91557-9_9.

64. Siu AL, US Preventive Services Task Force. Screening for depression in adults: US preventive services task force recommendation statement. JAMA. 2016;315(4):380–7. https://doi.org/10.1001/jama.2015.18392.

65. Smith MV, Brunetto WL, Yonkers KA. Identifying perinatal depression—sooner is better. USA: Contemporary OB/GYN; 2004.

66. Stockel LE, Epperson N, Barber JP. A meta-analysis of treatments for perinatal depression. Clin Psychol Rev. 2011;31(5):839–49. https://doi.org/10.1016/j.cpr.2011.03.009.

67. Sparks A, Cohen A, Adjao S, Arnold B, Chan J, Dang T, Sucato G. Perinatal depression screening, diagnosis, and treatment guideline. Oakland: Kaiser Permanente; 2018.

68. Thielke S, Vannoy S, Unutzer J. Integrating mental health and primary care. Prim Care. 2007;34(3):571–92. https://doi.org/10.1016/j.pop.2007.05.007.

69. Ukato N, Clare CA, Brulja M. Postpartum depression screening tools: a review. J Psychosom. 2018;59(3):211–9. https://doi.org/10.1016/j.psym.2017.11.005.

70. Wachs TD, Black MM, Engle P. Maternal depression: a global threat to children's health, development, and behavior and to human rights. Child Dev Perspect. 2009;3(1):51–9. https://doi.org/10.1177/1112617508008007.

71. Weinreb L, Byatt N, Simmons TA, Tenner K, Savageau JA. What happens to mental health treatment during pregnancy? Women's experience with prescribing providers. Psychiatry Q. 2018;85(3):349–55. https://doi.org/10.1007/s11126-014-9293-7.

72. Williams J, Ryan D, Thomas Peter K, Cadario B, D'Li D, BC Reproductive Mental Health Program. Best practice guidelines for mental health disorders in the perinatal period. Canada: BC Women's Hospital & Health Centre; 2014.

73. World Bank: World Bank country and lending groups. Washington: World Bank; 2010.

74. World Health Organization. World health statistics 2017. Geneva: WHO; 2017.

75. Yonkers KA, Wisner KL, Oberlander TF, Dell DL, Stotland N, Lockwood C. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009;31(5):403–13. https://doi.org/10.1016/j.genhosppsych.2009.04.003.

76. Zhou J, Feng L, Hu C, Pao C, Xiao L, Wang G. Associations among depressive symptoms, childhood abuse, neuroticism, social support and coping style in the population covering general adults, depressed patients, bipolar disorder patients and high-risk population for depression. Front Psychol. 2019. https://doi.org/10.3389/fpsyg.2019.01321.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.